National Poll Finds Seniors, Women and Americans from Across the Political Spectrum Reject FDA’s Consideration of Cost in Drug Approval Process
Image via Wikipedia
60 Plus, a national seniors-advocacy organization, released findings from a national poll demonstrating that Americans reject efforts by the Food and Drug Administration (FDA) to include “cost factors” as part of the drug approval process. In a case that many observers believe represents an emerging model for rationing care, the FDA is preparing to “de-label” Avastin, a drug used for late stage cancer patients in part because of cost concerns. Such an action could result in Avastin coverage for breast cancer patients being denied by Medicare, Medicaid and private insurance plans, while leaving the drug available to only those who can afford it. (PRWeb September 15, 2010) Read the full story at http://www.prweb.com/releases/60Plus/FDARationingPoll/prweb4523024.htm
